Pomegranate Juice Extract Decreases Cisplatin Toxicity on Peripheral Blood Mononuclear Cells

Abstract

Background: Lung cancer is one of the most prevalent cancers worldwide. Chemotherapy regimens, targeted against lung cancer, are considered an effective treatment; albeit with multiple fatal side effects. An alternative strategy, nowadays, is using natural products. Medicinal plants have been used, in combination with chemotherapy, to ameliorate side effects. Aims: This study aims to investigate the antitumor effect of pomegranate juice (Punica granatum) on human lung adenocarcinoma basal epithelial cells (A549), to check the effect, when combined with low dose cisplatin (CDDP), at different doses. We also have evaluated the potential protective effect of pomegranate on normal peripheral blood mononuclear cells (PBMC). Methods: Phytochemical screening of the extract was done using standard classical tests. Total phenolic and sugar contents were determined using the Folin–Ciocalteu and anthrone reagents, respectively. The antioxidant activity of pomegranate was estimated by the 2,2-diphenyl-1-picrylhydrazyl (DPPH) method. The viability of A549 cells and PBMC was evaluated using the neutral red assay. Results: Our results demonstrated that Punica granatum or pomegranate juice (with different concentrations: 150, 300, 600 µg/mL) contained high levels of flavonoids, alkaloids, tanins, lignins, terpenoids, and phenols. The DPPH method showed that pomegranate juice had a strong antioxidant scavenging activity. Neutral red showed that combining pomegranate juice with low dose CDDP (8 µg/mL) decreased the cell viability of A549 cells, by 64%, compared to treatment with CDDP or pomegranate alone. When added to low dose CDDP, pomegranate increased the viability of normal PBMC cells by 46%. Conclusions: These results demonstrated that pomegranate could potentiate the anticancer effect of low dose CDDP on human lung adenocarcinoma cells (A549 cells) and could as well decrease its toxicity on PBMC.

Tropical Fruits and Their Co-Products as Bioactive Compounds and Their Health Effects: A Review

“…In addition, the expression of N-Cadherin, Golgi phosphoprotein 3, matrix metalloproteinase-2, and matrix metalloproteinase-9 decreased. Similarly, Nasser et al [133] investigated the antitumor effect of pomegranate juice on human lung adenocarcinoma basal epithelial cells (A549). These authors reported that the treatment of A549 cells with pomegranate juice, which had a high content in flavonoids and non-flavonoid phenolic compounds, produced a decrease in the viability of these cells in a concentration-dependent manner.…”

Novel Pomegranate-Nanoparticles Ameliorate Cisplatin-Induced Nephrotoxicity and Improves Cisplatin Anti-Cancer Efficacy in Ehrlich Carcinoma Mice Model

“…Although few studies have reported that PE protects against CISP-induced toxicity [ 19 , 42 ], a number of other studies have shown that PE offers no protection against CISP-induced nephrotoxicity [ 5 , 14 , 21 , 32 ], and this may be due to the poor solubility. Hence, in this study, PE-NPs formulation was observed to improve its efficacy by enhancing the solubility.…”

Differential Antinociceptive Efficacy of Peel Extracts and Lyophilized Juices of Three Varieties of Mexican Pomegranate (Punica granatum L.) in the Formalin Test

“…Some alkaloids are known to have an effect in both phases of the formalin test [ 21 ]. In this context, we think that the short effect in phase 1 can be explained because pomegranate peel and pomegranate juice have some alkaloids like caffeine, peelletierine, and punigranate (a pyrrolidine type alkaloid), although they are not considered rich in these compounds [ 22 , 23 , 24 ]. Previous reports indicate that pomegranate peel of the Sefri variety has pain inhibition percentages (IPI) like ours (4 to 8.9%), but not the peel of the Amrouz variety, which achieved inhibition percentages of 37 to 75% (at doses of 25, 50, and 100 mg/kg intraperitoneal weight before injection of 20 µL of 2% formalin) [ 25 ].…”